Home | About us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionContact Us   |  Subscribe   |  Advertise   |  Login  Page layout
Wide layoutNarrow layoutFull screen layout
Lung India Official publication of Indian Chest Society  
  Users Online: 1956   Home Print this page  Email this page Small font size Default font size Increase font size


 
  Table of Contents    
LETTER TO EDITOR
Year : 2012  |  Volume : 29  |  Issue : 2  |  Page : 196-197  

HAART and ATT in the HIV-positive patient with tuberculosis


1 Department of Internal Medicine, Guangzhou Medical College, Guangzhou, Peoples Republic of China
2 Department of Radiation Oncology, Regional Cancer Centre, Shimla, Himachal Pradesh, India

Date of Web Publication24-Apr-2012

Correspondence Address:
Swaroop Revannasiddaiah
Department of Radiation Oncology, Regional Cancer Centre, Shimla, Himachal Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0970-2113.95349

Rights and Permissions

How to cite this article:
Jhiens ZZ, Revannasiddaiah S. HAART and ATT in the HIV-positive patient with tuberculosis. Lung India 2012;29:196-7

How to cite this URL:
Jhiens ZZ, Revannasiddaiah S. HAART and ATT in the HIV-positive patient with tuberculosis. Lung India [serial online] 2012 [cited 2019 Nov 14];29:196-7. Available from: http://www.lungindia.com/text.asp?2012/29/2/196/95349

Sir,

We congratulate the authors Jaryal et al. [1] for their exemplary work of research which was published in the article titled "Manifestations of tuberculosis in HIV/AIDS patients and its relationship with CD4 count" published in Lung India, vol. 28, issue 4.

We would like to suggest that future studies would be more complete if due consideration is given to another extra criterion, i.e. the use of highly active antiretroviral therapy (HAART). Future analysis should preferably include the incidence and presentation patterns of pulmonary tuberculosis (PTB) and extrapulmonary tuberculosis (EPTB) among Human immunodeficiency virus (HIV)-positive patients stratified into groups taking HAART and not taking HAART. Such an analysis, if done, could answer a few queries, such as:

  • Whether HAART initiation reduces the risk of central nervous system (CNS) involvement from tuberculosis (TB)?
  • Whether HAART initiation reduce the ratio of EPTB: PTB among HIV-positive patients?
A point of concern that we noted was regarding the authors' conclusion that "early diagnosis of TB and prompt institution of anti-tubercular treatment (ATT) reduces mortality and morbidity significantly." We would like to state that the initiation of ATT among patients on HAART could be akin to entering "uncharted waters", there could be combined toxicities of HAART and ATT: [2],[3],[4],[5]

  • Would the combination of ATT and HAART do more good than harm?
  • Should there be criteria regarding patient selection for ATT when already on HAART?
  • Should HAART regimens be modified to remove drugs known to be hepatotoxic?
Concerns also exist regarding the initiation of HAART in a HIV-positive patient diagnosed with disseminated TB. TB is a disease characterized as a granulomatous inflammatory condition, with the participation of macrophages, T-lymphocytes, B-lymphocytes, etc. in the pathogenesis of the "tubercular granuloma." Since HAART is known to induce immune reconstitution, [2],[3] the effects on the pathophysiology of TB could be comparable to a "double edged sword."

 
   References Top

1.Jaryal A, Raina R, Sarkar M, Sharma A. Manifestations of tuberculosis in HIV/AIDS patients and its relationship with CD4 count. Lung India 2011;28:263-6.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: Case definitions for use in resource-limited settings. Lancet Infect Dis 2008;8:516-23.  Back to cited text no. 2
    
3.Leone S, Nicastri E, Giglio S, Corpolongo A, Narciso P, Acone N. Tuberculosis-associated immune reconstitution inflammatory syndrome. Infez Med 2008;16:193-9.  Back to cited text no. 3
    
4.Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362:697-706.  Back to cited text no. 4
    
5.Schluger NW. Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients. Clin Infect Dis 1999;28:130-5.  Back to cited text no. 5
    




 

Top
  
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed1232    
    Printed50    
    Emailed0    
    PDF Downloaded346    
    Comments [Add]    

Recommend this journal